Dyadic International Inc DYAI:NASDAQ

Last Price$3.04NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change-0.01(0.33%)
Bid (Size)$3.04 (5)
Ask (Size)$3.05 (69)
Day Low / High$2.90 - 3.05
Volume17.6 K
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Dyadic International Inc ( NASDAQ )

Price: $3.04
Change: -0.01 (0.33%)
Volume: 17.6 K
4:00PM ET 7/01/2022
 
 

Curis Inc ( NASDAQ )

Price: $0.94
Change: -0.04 (4.50%)
Volume: 1.9 M
4:00PM ET 7/01/2022
 
 

Cue Biopharma Inc ( NASDAQ )

Price: $2.45
Change: -0.04 (1.61%)
Volume: 323.7 K
4:00PM ET 7/01/2022
 
 

Aspira Women's Health Inc ( NASDAQ )

Price: $0.73
Change: +0.14 (24.66%)
Volume: 757.8 K
4:00PM ET 7/01/2022
 
 

Cortexyme Inc ( NASDAQ )

Price: $2.52
Change: +0.30 (13.51%)
Volume: 714.8 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Dyadic International Enters Collaboration to Develop Animal-Free Ingredient Products
10:31AM ET 5/11/2022 MT Newswires

Dyadic International (DYAI) said Wednesday it has entered into an agreement with a global food ingredients company to come up with animal-free products...

Dyadic Says Licensee Epygen Gets Indian Government Funding to Develop COVID-19 Vaccine
9:41AM ET 4/13/2022 MT Newswires

Dyadic International (DYAI) said Wednesday its licensee Epygen Biotech received funding from the Indian government to develop a low-cost COVID-19 vaccine...

--HC Wainwright Adjusts Price Target on Dyadic International to $6 From $7, Reiterates Buy Rating
11:41AM ET 4/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Dyadic International, Phibro Animal Health Strike Licensing Deal for Animal Health Vaccine
10:48AM ET 2/10/2022 MT Newswires

Dyadic International (DYAI) and Phibro Animal Health (PAHC) said Thursday they entered into a licensing deal to develop a cell-based poultry vaccine...

Company Profile

Business DescriptionDyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL. View company web site for more details
Address140 Intracoastal Pointe Drive
Jupiter, Florida 33477-5094
Phone+1.561.743.8333
Number of Employees8
Recent SEC Filing06/14/20224
President, Chief Executive Officer & DirectorMark A. Emalfarb
Chief Financial OfficerPing W. Rawson
Vice President-Research & Business DevelopmentRonen Tchelet
MD-Business Development & LicensingMatthew S. Jones

Company Highlights

Price Open$3.04
Previous Close$3.05
52 Week Range$1.74 - 6.89
Market Capitalization$85.9 M
Shares Outstanding28.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.44
Beta vs. S&P 500N/A
Revenue$1.3 M
Net Profit Margin-473.31%
Return on Equity-61.45%

Analyst Ratings as of 12/16/2021

Buy
2
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset